Inpalix

Paliperidone, the active ingredient in Inpalix, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adult patients, helping to control psychotic symptoms and stabilize mood.

GNH USA supplies Inpalix as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide with reliable logistics, quality assurance, and regulatory support. The company adheres to stringent quality standards and offers flexible ordering options for institutional buyers.

Paliperidone, an atypical antipsychotic, modulates dopaminergic and serotonergic pathways to manage psychotic disorders.

- Schizophrenia: reduces positive and negative symptoms, improving overall functioning. - Schizoaffective disorder: stabilizes mood swings and psychotic features, aiding long‑term control. - Maintenance therapy of schizophrenia: provides sustained symptom control to prevent relapse.

Paliperidone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Somnolence - Weight gain - Increased prolactin levels - Constipation - Dry mouth

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Seizures - Agranulocytosis - Myocarditis

When prescribing Paliperidone, clinicians should observe several safety considerations. - Monitor for worsening psychosis: assess symptom changes regularly. - Evaluate metabolic parameters: check weight, glucose, and lipid levels. - Assess cardiovascular status: watch for orthostatic hypotension and QT prolongation. - Observe for hyperprolactinemia: monitor menstrual changes and galactorrhea. - Use caution in elderly with dementia: increased risk of mortality. - Store at ambient temperature: keep in original packaging, protect from moisture.

Paliperidone interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): may reduce effectiveness. - Other antipsychotics: risk of additive QT prolongation. - CNS depressants: enhanced sedation and respiratory depression. - QT‑prolonging agents: heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood pressure lowering. - Anticholinergic drugs: increased anticholinergic burden. - Lithium: potential nephrotoxicity. - Carbamazepine: moderate enzyme induction. - Alcohol: may intensify central nervous system effects.